Study guide

8.3 Continuous Quality Improvement, Risk Management, and Inventory Control

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

8.3 Continuous Quality Improvement, Risk Management, and Inventory Control

Key Takeaways Explain This Topic AI

The PDSA (Plan-Do-Study-Act) cycle is the most widely used continuous improvement framework; successful small-scale tests are standardized and scaled, while unsuccessful ones are iterated.

Six Sigma uses DMAIC and targets at most 3.4 defects per million opportunities; Lean focuses on eliminating the seven TIMWOOD wastes.

ISMP high-alert medications include anticoagulants, insulin, opioids, chemotherapy, and concentrated electrolytes; prevention uses independent double checks, smart pumps, and tall-man lettering.

DEA requires Form 106 within one business day of discovery of theft, loss, or significant diversion of controlled substances.

Recall classes: Class I carries reasonable probability of serious harm or death, Class II temporary or reversible harm, and Class III unlikely harm.

Last updated: July 2026

Continuous Quality Improvement, Risk Management, and Inventory Control

Quick Answer: Pharmacy quality and risk programs apply structured improvement frameworks (PDSA, Lean, Six Sigma), rigorous medication-error analysis, and disciplined inventory control to protect patients and sustain operations. Controlled substances add DEA-specific requirements including biennial inventory and Form 106 for theft or loss.

Continuous Quality Improvement (CQI)

CQI is a structured, data-driven approach to improving processes over time. Unlike one-time fixes, CQI treats quality as an ongoing organizational commitment.

The PDSA Cycle

The Plan-Do-Study-Act (PDSA) cycle is the most widely used improvement framework.

Plan — define the problem, set measurable objectives, predict results, and design a small-scale test.

Do — implement the test on a small scale and document observations.

Study — compare results against predictions; analyze variation and unintended effects.

Act — adopt, adapt, or abandon. If successful, scale and standardize; if not, iterate with a revised plan.

Other Improvement Methodologies

Six Sigma — uses DMAIC (Define, Measure, Analyze, Improve, Control) to reduce defects to at most 3.4 per million opportunities; emphasizes statistical control.

Lean — focuses on eliminating waste (defects, overproduction, waiting, non-utilized talent, transportation, inventory, motion, extra-processing — the "TIMWOOD" wastes).

Root cause analysis (RCA) — retrospective investigation after a sentinel event, asking "5 Whys" to identify systemic causes rather than blaming individuals.

Failure Mode and Effects Analysis (FMEA) — prospective, team-based risk assessment that scores failure modes by severity × occurrence × detectability to prioritize mitigation.

Medication Error Reduction

The Institute for Safe Medication Practices (ISMP) publishes high-alert medication lists (anticoagulants, insulin, opioids, chemotherapy, concentrated electrolytes) that bear heightened risk of catastrophic harm. Prevention strategies include independent double checks, smart-pump dose libraries, tall-man lettering, and standardized order sets. Error reporting flows to MedMARX (national, anonymous) and FDA MedWatch for serious adverse events. A just culture model distinguishes human error (coachable) from at-risk behavior (coachable plus system redesign) and reckless behavior (sanction), encouraging reporting without minimizing accountability.

  • Error Type Example Prevention Strategy
  • Prescribing Wrong dose, wrong drug CPOE with clinical decision support
  • Transcription Misreading abbreviation Eliminate error-prone abbreviations (U, IU, QD)
  • Dispensing Wrong product selection Bar-code scanning, robotics
  • Administration Wrong route, wrong rate Smart pumps, independent double checks
  • Monitoring Missed adverse effect Documentation prompts, MTM review
  • Risk Management

Risk management is the systematic identification, analysis, and mitigation of exposures. Pharmacy risks include medication errors, malpractice and professional liability (covered by professional liability insurance), privacy breaches under HIPAA, and financial fraud. Incident reporting — internal forms capturing near-misses and actual events — feeds CQI. Sentinel events trigger RCA and often a report to The Joint Commission. The pharmacist-in-charge maintains liability coverage and ensures protocol-driven delegation to technicians within state scope.

  • Procurement and Inventory Control
  • Procurement

Most pharmacies purchase through wholesale distributors under a prime vendor agreement (PVA) that offers volume discounts and predictable delivery in exchange for approximately 80% of purchases. Group purchasing organizations (GPOs) aggregate buying power across members to negotiate manufacturer rebates. Pharmacies must verify wholesalers are licensed and maintain pedigree documentation per the Drug Supply Chain Security Act (DSCSA).

Inventory Control

ABC analysis — classifies inventory by cost: A (top 20% of SKUs, 70 to 80% of spend), B (next 30%), C (bottom 50%). A-items receive tight control; C-items looser.

Reorder point = (average daily usage × lead time) + safety stock.

Turnover rate = cost of goods sold divided by average inventory; healthy turnover is approximately 12 times per year.

Drug shortages — managed via ASHP guidelines: identify therapeutic alternatives, conserve supply, communicate with prescribers, and avoid hoarding.

Controlled Substances

DEA registrants must maintain a biennial inventory (every 2 years, on any date the registrant selects) of all Schedule II to V substances, recorded without witness for Schedules III to V and with a witness for Schedule II. Dispensing records (DEA Form 222 for Schedule II transfers; order records for III to V) are retained for 2 years. Theft, loss, or significant diversion must be reported to DEA on Form 106 within one business day of discovery and to the state board per local rules.

Expiration, Recalls, and Storage

Expiration date management — first-expire-first-out (FEFO) stocking; quarterly scans to remove short-dated stock.

Recalls — Class I (reasonable probability of serious adverse health consequences or death), Class II (temporary or medically reversible adverse health consequences), Class III (not likely to cause adverse health consequences). Pharmacies follow manufacturer or FDA instructions for return or disposal and document patient notification when dispensed product is affected.

Storage requirements — USP General Chapter <659> defines controlled room temperature (20 to 25°C, excursions 15 to 30°C), refrigeration (2 to 8°C), and freezing (-25 to -10°C). Daily temperature logs are standard practice.

Pharmacy Compounding Quality Assurance

USP <795> (nonsterile), <797> (sterile), and <800> (hazardous drugs) define quality standards for ingredients, environment, personnel competency, and beyond-use dating. <797> requires ISO-classified cleanroom suites, environmental monitoring, and gloved fingertip sampling. <800> mandates containment primary engineering controls (C-PEC) and containment secondary engineering controls (C-SEC) for hazardous drug handling to protect personnel and patients.

Loading diagram... Plan-Do-Study-Act (PDSA) Improvement Cycle